Patents by Inventor Christopher N. SILK

Christopher N. SILK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA Methylation and Mutational Analysis Methods for Bladder Cancer Surveillance
    Publication number: 20230374604
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Application
    Filed: April 4, 2023
    Publication date: November 23, 2023
    Applicant: Genomic Health, Inc.
    Inventors: Margarita LOPATIN, Athanasios TSIATIS, Christopher N. SILK, David P. MILLER, Michael R. CRAGER, Phillip FEBBO, Dejan KNEZEVIC
  • DNA methylation and mutational analysis methods for bladder cancer surveillance
    Patent number: 11649506
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 16, 2023
    Assignee: Genomic Health, Inc.
    Inventors: Margarita Lopatin, Athanasios Tsiatis, Christopher N. Silk, David P. Miller, Michael Crager, Phillip Febbo, Dejan Knezevic
  • DNA Methylation and Mutational Analysis Methods for Bladder Cancer Surveillance
    Publication number: 20200165686
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Application
    Filed: May 17, 2018
    Publication date: May 28, 2020
    Applicant: Genomic Health, Inc.
    Inventors: Margarita LOPATIN, Athanasios TSIATIS, Christopher N. SILK, David P. Miller, Michael CRAGER, Phillip FEBBO, Dejan KNEZEVIC